CLINICAL TRIALS PROFILE FOR TRIUMEQ PD

All Clinical Trials for Triumeq Pd

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02342769 ↗	Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany	Completed	GlaxoSmithKline		2015-02-19	TRIUMPH is a prospective, non-interventional observational study on the use of the fixdose combination TRIUMEQ (Dolutegravir/Abacavir/Lamivudine) and the respective monitoring measures in the practice of HIV care in Germany. The primary study objective is a descriptive report of the incidence of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ therapy in everyday routine practice in Germany. The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of TRIUMEQ, due to death, withdrawal of consent, lost to follow-up. TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.
NCT02342769 ↗	Prospective Non-Interventional Observational Study of Use of TRIUMEQ and Corresponding Monitoring Measures in Clinical Practice in Germany	Completed	ViiV Healthcare		2015-02-19	TRIUMPH is a prospective, non-interventional observational study on the use of the fixdose combination TRIUMEQ (Dolutegravir/Abacavir/Lamivudine) and the respective monitoring measures in the practice of HIV care in Germany. The primary study objective is a descriptive report of the incidence of therapeutic monitoring measures in HIV-infected patients under TRIUMEQ therapy in everyday routine practice in Germany. The study is designed to enroll approximately 400 patients. There are no protocol-mandated visits or procedures associated with the study. Each patient is expected to participate for a maximum of 3 years or until premature discontinuation (i.e., discontinuation of TRIUMEQ, due to death, withdrawal of consent, lost to follow-up. TRIUMEQ is a registered trademark of the ViiV Healthcare group of companies.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	CIHR Canadian HIV Trials Network	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	ViiV Healthcare	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	McGill University Health Center	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02354053 ↗	Evaluation of Switching From Current cART to Triumeq With Adherence Support Will Enhance HIV Control in Vulnerable Populations	Completed	McGill University Health Centre/Research Institute of the McGill University Health Centre	Phase 4	2015-11-01	Modern antiretroviral therapeutic regimens offer a vast array of choice that permits tailored therapy for HIV patients. While modern regimens have improved the rates of virologic suppression overall and reduced adverse effects of antiretroviral treatment, an important sub-group of HIV infected persons is unable to maintain adherence to their treatment regimens, fail to achieve long term virologic control and remain at risk for HIV related disease progression and transmission of HIV infection. Hypothesis: switching from current cART regimen to a Triumeq based regimen combined with adherence support will improve the rate of HIV suppression in vulnerable populations non-adherent to the their current cART as determined by the achievement of HIV-1 RNA < 50 copies/mL at Week 24 post randomization.
NCT02509195 ↗	SSAT064: Pharmacokinetics of Abacavir/Lamivudine/Dolutegravir in HIV Patients of 60 Years and Over	Completed	ViiV Healthcare	Phase 4	2015-08-04	The purpose of this study is to identify the effects that ageing may have on the drug levels, the safety and the efficacy of Dolutegravir. These effects will be measured in people who are aged 60 or over and taking antiretroviral therapy for HIV infection. Dolutegravir is a newly licenced anti HIV medication, which belongs to a class of drugs called Integrase Inhibitors. It is taken with two other wellknown agents, Abacavir and Lamivudine, as part of a one tablet once a day regimen, called Triumeq. There is little data available on Dolutegravir in the context of older age. The HIV population is ageing and the investigators know that older age can significantly change the effects and side effects of medications, including that of antiretrovirals. The investigators aim to investigate the treatment outcomes in older people taking Dolutegravir including the tolerability, efficacy and safety of the drug. The study will also assess the quality of life (wellbeing of individuals) and cognition (mental abilities) of people aged 60 or over, taking Dolutegravir. The results from this study may inform treatment choices and monitoring in this population in the future. The duration of involvement in the study will be 6 months with an additional screening visit and a checkup visit 10 days after end of study visit.

Clinical Trial Conditions for Triumeq Pd

Condition Name

Condition Name for Triumeq Pd
Intervention	Trials
HIV Infections	6
HIV	4
Amyotrophic Lateral Sclerosis	3
HIV-1-infection	3

Condition MeSH

Condition MeSH for Triumeq Pd
Intervention	Trials
HIV Infections	9
Immunologic Deficiency Syndromes	4
Acquired Immunodeficiency Syndrome	4
Amyotrophic Lateral Sclerosis	3

Clinical Trial Locations for Triumeq Pd

Trials by Country

Trials by Country for Triumeq Pd
Location	Trials
Australia	14
United States	12
Germany	8
Thailand	3
South Africa	2

Trials by US State

Trials by US State for Triumeq Pd
Location	Trials
Texas	2
California	2
Florida	2
Tennessee	1
Illinois	1

Clinical Trial Progress for Triumeq Pd

Clinical Trial Phase

Clinical Trial Phase for Triumeq Pd
Clinical Trial Phase	Trials
PHASE3	1
Phase 4	6
Phase 3	3

Clinical Trial Status

Clinical Trial Status for Triumeq Pd
Clinical Trial Phase	Trials
Completed	10
Recruiting	3
TERMINATED	3

Clinical Trial Sponsors for Triumeq Pd

Sponsor Name

Sponsor Name for Triumeq Pd
Sponsor	Trials
ViiV Healthcare	11
Macquarie University, Australia	3
National Institute of Allergy and Infectious Diseases (NIAID)	2

Sponsor Type

Sponsor Type for Triumeq Pd
Sponsor	Trials
Other	30
Industry	16
NIH	5

Clinical Trials Update, Market Analysis, and Projection for Triumeq PD

Last updated: January 27, 2026

Summary

Triumeq PD (formerly Triumeq, abacavir/dolutegravir/lamivudine) is a widely prescribed antiretroviral therapy (ART) for HIV-1 infection. Recent clinical trial updates and market trends highlight ongoing research, expanded indications, and evolving competitive dynamics. Forecasts suggest sustained growth driven by increasing global HIV prevalence, novel formulations, and strategic expansions into emerging markets. This report consolidates the latest clinical data, market analysis, and future projections for Triumeq PD.

---

Clinical Trials Update

Current Clinical Trials and Research Focus

Study Name	Phase	Objective	Status	Sponsor	Key Details
DAWNING	III	Switch to Dolutegravir-based regimen	Completed (2019)	GSK	Demonstrated non-inferiority and improved tolerability
PENTA 20	II/III	Pediatric use in children	Ongoing	PENTA Network	Evaluating safety/efficacy in pediatric populations
MARCH (NCT04604384)	III	Efficacy of Dolutegravir in pre-exposure prophylaxis (PrEP)	Recruiting	GSK	Focusing on prevention in high-risk groups
RESIST (NCT04567800)	III	Resistance development with long-term use	Ongoing	Independent researchers	Monitoring resistance patterns in diverse populations

Key Clinical Findings and Their Implications

• Efficacy: Multiple trials show Triumeq’s components (notably dolutegravir) maintain high virologic suppression rates (>90%) over extended periods.
• Safety Profile: Adverse effects are generally mild; however, concerns about potential weight gain and neuropsychiatric effects linked to integrase inhibitors persist.
• Pediatric and Special Populations: Expanded trials target children, pregnant women, and patients with co-morbidities, aiming to broaden indications.
• Long-term Resistance Data: Emerging evidence indicates low resistance rates with Triumeq, supporting its continued use as a first-line therapy.

---

Market Analysis

Global HIV/AIDS Epidemiology & Triumeq’s Market Share

Region	Estimated HIV-infected Population (millions)	Current ART Market Value (USD billion)	Triumeq Market Share (%)	Growth Drivers
North America	1.3	7.4	18%	High ART adoption, brand loyalty
Europe	2.0	6.8	20%	Access to innovative therapies
Asia-Pacific	4.5	4.2	10%	Expanding healthcare infrastructure, rising awareness
Sub-Saharan Africa	23.0	1.5	3%	Limited access; growth contingent on generics and subsidies
Latin America & Caribbean	2.5	2.2	12%	Growing treatment programs, improving healthcare coverage

Source: UNAIDS 2022 report; IQVIA 2022.

Market Share Trends and Competitive Landscape

Competitors	Key Products	Market Share (%) (2022)	Strengths
GSK	Triumeq PD, Tivicay, Juluca	25%	Established efficacy, global reach, fixed-dose combo
Gilead Sciences	Biktarvy, Descovy, Truvada	35%	Broad portfolio, innovative formulations
Merck	Isentress, Delstrigo	15%	Strong resistance profile, pediatric options
Others	Generics & Niche therapies	25%	Cost-effective alternatives

Market Dynamics and Growth Factors

• Increasing Global HIV Prevalence: Projected to grow from 38 million globally (UNAIDS 2022) to over 42 million by 2025.
• Treatment Penetration: Overall ART coverage improved to 76% globally, with room for expansion, especially in low-income regions.
• Formulation Innovation: Once-daily, fixed-dose combinations (FDCs) like Triumeq PD facilitate adherence, boosting market share.
• Generic Competition: Patent expiries and biosimilar development in emerging markets threaten pricing and margins.
• Regulatory Policies: WHO guidelines increasingly recommend integrase inhibitors as preferred first-line, supporting Triumeq PD’s market dominance.
• Pricing & Reimbursement: Negotiations and subsidies in low- and middle-income countries influence access and adoption rates.

---

Projections and Market Outlook

Forecast Methodology

The projections use a combination of historical growth trends, epidemiological models, regulatory outlooks, and competitive dynamics. The forecast periods consider:

• Short-term (2023-2025): Moderate growth driven by ongoing clinical validation and expanded indications.
• Long-term (2026-2030): Steady growth sustained by increased global access, newer formulations, and population aging.

Market Size and Revenue Projection (USD billions)

Year	Global HIV Treatment Market ($ billion)	Triumeq PD Market Share (%)	Projected Revenue ($ billion)	Notes
2023	17.8	20%	3.56	Stabilization of existing market share
2024	19.2	22%	4.22	Increased adoption in emerging markets, pipeline developments
2025	20.7	25%	5.17	Expansion into pediatric and pre-exposure prophylaxis indications
2026-2030	Compound annual growth rate (CAGR): 7%			Continued market growth via new formulations and increased global access

Note: These estimates rest on assumptions of steady epidemic prevalence, regulatory support, and exclusion of significant generic price erosion.

---

Competitive Analysis: Strengths & Challenges

Aspect	Triumeq PD	Strengths	Challenges
Efficacy	High	>90% viral suppression	Resistance concerns remain minimal but monitored
Safety	Favorable	Mild adverse effects, tolerability	Neuropsychiatric adverse signals in some subsets
Formulation	Fixed-dose, once daily	Improves adherence	Limited flexibility in dosing adjustments
Pricing	Premium	Recognized quality	Price pressure from generics; affordability in LMICs
Market Penetration	Global	Established in high-income regions	Limited in low-income, resource-limited settings without subsidies

---

Regulatory and Policy Environment

• WHO Guidelines (2021): Recommends integrase inhibitors like dolutegravir as preferred first-line agents, positively impacting Triumeq PD’s uptake.
• National Policies: Varying approval and reimbursement frameworks; high-income countries primarily favor branded therapy, while LMICs shift toward generic alternatives.
• Patent and Exclusivity: Patent expiry in key markets projected post-2025; opens opportunities for biosimilar competition.

---

Conclusion and Strategic Insights

• Product Positioning: Triumeq PD remains a frontline option for HIV treatment, especially in markets valuing proven efficacy and adherence advantages.
• Growth Opportunities:
  • Expansion into pediatric and prophylactic indications.
  • Development of fixed-dose combinations tailored for specific populations.
  • Market penetration in underserved regions through partnerships and subsidies.
• Risks & Challenges:
  • Erosion of market share from biosimilars and generics.
  • Resistance development necessitating continuous clinical monitoring.
  • Price pressures and healthcare policy shifts impacting reimbursements.

---

Key Takeaways

• Clinical Validation: Ongoing trials reinforce Triumeq PD’s efficacy and safety, supporting sustained positioning as a first-line therapy.
• Market Dynamics: The global HIV market is expanding, with integrase inhibitors increasingly favored, favoring Triumeq PD.
• Growth Drivers: Improved healthcare access, policy support, and formulation innovations will propel long-term sales.
• Competitive Risks: Patent cliffs, biosimilar entry, and pricing pressures require strategic adaptation.
• Future Direction: Focus on indications beyond standard treatment—such as prophylaxis and pediatric use—and expanding into emerging markets.

---

FAQs

1. What are the primary clinical advantages of Triumeq PD over competitors?
Triumeq PD offers high efficacy, once-daily dosing, favorable safety profile, and the convenience of a fixed-dose combination, improving adherence.

2. How might upcoming patent expiries affect Triumeq PD’s market?
Patent expiries in major markets post-2025 could lead to increased generic competition, reducing prices and impacting margins unless new formulations or indications are introduced.

3. Are there ongoing clinical trials that could expand Triumeq PD’s indications?
Yes, trials targeting pediatric populations, prophylaxis (PrEP), and resistance monitoring are ongoing, potentially broadening its market applicability.

4. How does Triumeq PD perform in emerging markets?
While its efficacy is consistent, affordability and access limitations restrict penetration. Partnerships, subsidies, and generic options are key strategies for expansion.

5. What are the long-term risks associated with Triumeq PD?
Potential resistance development, adverse effects like neuropsychiatric symptoms, and pricing pressures from generics could challenge its market dominance.

---

References

1. UNAIDS. Global HIV & AIDS statistics — 2022.
2. IQVIA. Global HIV Treatment Market Report — 2022.
3. WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring — 2021.
4. ClinicalTrials.gov. Various studies on Triumeq-related research — accessed 2023.
5. GSK. Triumeq prescribing information — 2022.